CNS

#Clinical trials #CNS #Drug development #Drug discovery #Rare disease

The difficulties of rare disease clinical trials

Late-stage biotech Minoryx is developing a therapy (leriglitazone) targeting patients with the rare progressive CNS disease cerebral adrenoleukodystrophy (cALD). If approved, it would give patients another choice of treatment options outside of stem cell transplants and gene therapies. Data presented last year for leriglitazone showed it stopped cALD disease progression… Read More

#Exclusive Content

#App note #CNS #In vitro #In vitro assays #iPSC #Neuroscience

App Note: Optimisation for a live cell in vitro neuronal activity assay

Human induced pluripotent stem cell (iPSC) derived models are increasingly being used for in vitro studies of the human central nervous system. Growth factors and cytokines are critical in these models for cell growth, differentiation, and survival, but their study is complicated by factors like unknown commercial media compositions and… Read More

#News

AI brain
#CNS #Events #Genomics #Neuroscience #SLAS2025

Learn about the brain genomic positioning system with DDW

Graham T Dempsey, PhD, Co-founder and Chief Scientific Officer, Quiver Biosciences will be speaking at the DDW SLAS2025 track – Concept to Cure: Curiosity and Lab Automation in Drug Discovery. SLAS2025 is on 25-29 January 2025, in San Diego, USA. Graham Dempsey This free… Read More

#News

#Applied Therapeutics #CNS #FDA #Genetic diseases #Rare disease

Patient groups urge FDA to reconsider govorestat rejection

The US Food and Drug Administration’s (FDA) decision not to approve govorestat, a central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI) for Classic Galactosemia, has been met with criticism from patient groups.  Govorestat is the only investigational treatment to be evaluated for Galactosemia, a rare genetic disease that can be… Read More

#News #Regulatory #Trending News

Gene therapy
#CNS #Financing #Gene therapy #Neurogene #Private investment

Oversubscribed $200m private placement for gene therapy company

Neurogene revealed it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million. Neurogene is developing approaches and treatments which it hopes will address the limitations of conventional gene therapy in central… Read More

#Business & Investment #News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug discovery #Neuroscience

The latest advancements driving neuroscience drug discovery research

In this webinar, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Dr Klein shares how Dewpoint applies insights into… Read More

Webinar date:
Supported by Apconix
#Webinars

Neuroscience innovation
#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Last chance: Driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

What are the latest advancements driving neuroscience drug discovery?

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Webinar on driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

The latest advancements driving neuroscience drug discovery

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

Dementia
#CNS #IRLAB Therapeutics #Neurodegenerative disorders #Parkinson's #Phase I trial

Drug candidate for apathy enters Phase I trials

Swedish company IRLAB Therapeutics has initiated a Phase I study of IRL757, its drug candidate for apathy – a condition associated with Parkinson’s disease and other CNS diseases. IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This… Read More

#News

RNA strand
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #CNS #Genetic diseases #mRNA #RNA #Turning Science into Business

Turning science into business: Amplifying mRNA by targeting regRNAs

DDW’s Diana Spencer speaks to Josh Mandel-Brehm, CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. DS: CAMP4 leverages research from co-founder Richard Young on how regulatory RNA… Read More

#Business & Investment #Exclusive Content

#Biologics / Biotechnology #Cell therapy #CNS #Financing #Kenai Therapeutics #Neurology #Parkinson's

$82m investment in cell therapies for neurological diseases

Biotechnology company Kenai Therapeutics has raised $82 million in a Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group. Kenai Therapeutics previously raised seed funding under the name Ryne Bio. “We are grateful for the support of a syndicate of leading life science investors… Read More

#Business & Investment #News

A scientist examines brain scans on a large screen
#CNS #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife

The era of precision neuroscience

Listen to this article on the DDW Podcast: Dr Steve Gardner, CEO of the computational biology company PrecisionLife, explores the challenges of achieving precision medicine in complex CNS conditions and explains how new precision neuroscience approaches are benefitting pharmaceutical companies who are again investing in the field to develop better treatments… Read More

#Exclusive Content

Networked world map
#CNS #Neuraxpharm #Pharmaceuticals

Neuraxpharm expands outside Europe into Brazil and Mexico 

Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has established affiliates in Brazil and Mexico, the two largest pharmaceutical markets in Latin America1, as first steps in its expansion outside of Europe.  As part of the expansion into Brazil, Neuraxpharm has… Read More

#News #Regulatory

Node structures in the central nervous system
#CNS #Collaboration #Nanopharmaceutics #PrecisionLife

Collaboration to accelerate and de-risk CNS clinical development 

PrecisionLife and Nanopharmaceutics have entered a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.  This collaboration between PrecisionLife and Nanopharmaceutics uses mechanistic patient stratification biomarkers to inform clinical trial design and transform the lives of patients. … Read More

#News